Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Amphista Therapeutics Ltd.
Headquarters: Chapelhall, United Kingdom
Website: http://www.amphista.com/
Year Founded: 2017
Status: Private
BioCentury | Jan 15, 2025
Management Tracks
Auspitz becomes managing partner at Curie.bio
Plus: Amphista names Paul Medeiro CBO, and updates from Apellis, Forbion, Eqt, Egle, Spero, Molecular Templates and more
BioCentury | Oct 3, 2024
Discovery & Translation
Type 2 cytokines for durable cancer remission, drugging GTPases: BioCentury’s Science Spotlight
BioCentury’s roundup of translational innovations
BioCentury | Sep 12, 2024
Management Tracks
Ovid promotes Alexander to COO
Plus: Tyra hires Warner as CMO and updates from Senisca, Closed Loop, NanoSyrinx and more
BioCentury | Sep 4, 2024
Management Tracks
Evers leaving Evotec as CBO
Plus: C-suite changes at Dyne, and updates from Novocure, Amphista, reMYND, Belite Bio, Forward and more
BioCentury | Jun 6, 2024
Discovery & Translation
Science Spotlight: Engineered CD47 protects CAR T cells from macrophages and more
BioCentury’s roundup of translational innovations
BioCentury | May 23, 2024
Product Development
Amphista degrades a cancer target using a non-traditional ligase
Amphista’s targeted glues combine the advantages of PROTACs and molecular glues to create selective, orally bioavailable therapies
BioCentury | Feb 24, 2024
Discovery & Translation
Science spotlight: New class of molecular glues, gene therapy for FTD/ALS and more
BioCentury’s roundup of translational innovations
BioCentury | Dec 7, 2023
Management Tracks
Versanis vet Pruzanski becomes Abcuro’s chair
Plus: Alentis hires Velji as CBO and updates from Empress, Ribbon, Octave, Camena, OM and Transgene
BioCentury | Jun 26, 2023
Management Tracks
Charl van Zyl to succeed Dunsire at Lundbeck
Plus: Raj Kannan named CEO at I-Mab, and updates from uniQure, Immodulon, Ichnos and more
BioCentury | May 3, 2023
Management Tracks
Filius to depart Galapagos
Plus: Modis joins Amphista as CSO and updates from ObsEva, CS Genetics, Resolution and Newron
Items per page:
1 - 10 of 25